Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average rating of “Buy” from the twenty-four ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $647.90.
Several equities research analysts have commented on REGN shares. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $525.00 to $477.00 and set an “equal weight” rating on the stock in a research report on Monday, April 26th. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. Robert W. Baird restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. Smith Barney Citigroup upped their price objective on Regeneron Pharmaceuticals from $575.00 to $584.00 in a research report on Thursday, January 14th. Finally, FIX raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $635.00 to $575.00 in a research note on Friday, January 8th.
Several large investors have recently modified their holdings of the stock. Alliancebernstein L.P. increased its position in shares of Regeneron Pharmaceuticals by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock worth $851,889,000 after purchasing an additional 208,936 shares during the last quarter. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $506,839,000. Bank of New York Mellon Corp boosted its holdings in Regeneron Pharmaceuticals by 1.0% during the 4th quarter. Bank of New York Mellon Corp now owns 828,264 shares of the biopharmaceutical company’s stock valued at $400,141,000 after acquiring an additional 8,138 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Regeneron Pharmaceuticals by 8.7% during the 4th quarter. UBS Asset Management Americas Inc. now owns 643,442 shares of the biopharmaceutical company’s stock valued at $310,853,000 after acquiring an additional 51,243 shares during the period. Finally, Swiss National Bank boosted its holdings in Regeneron Pharmaceuticals by 4.6% during the 4th quarter. Swiss National Bank now owns 596,122 shares of the biopharmaceutical company’s stock valued at $287,992,000 after acquiring an additional 26,000 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a net margin of 38.28% and a return on equity of 28.97%. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.40 billion. During the same quarter in the prior year, the company earned $7.50 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals will post 27.23 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.